Analysts Maintain Strong Buy Consensus on Eli Lilly Amid Conflicting Healthcare Sector Sentiments
Key Insights
Goldman Sachs analyst Asad Haider reiterated a Buy rating on Eli Lilly with a $1,283.00 price target, reflecting continued confidence in the pharmaceutical giant.
Truist Financial's Srikripa Devarakonda also maintained a Buy rating on Eli Lilly, with shares trading at $1,163.73 as of early June.
The overall analyst consensus on Eli Lilly remains a Strong Buy with an average price target of approximately $1,267, implying an 11-19% upside from current levels.
Wall Street analysts continue to express strong conviction in Eli Lilly & Co (NYSE: LLY), with multiple major financial institutions reiterating Buy ratings on the pharmaceutical leader in recent weeks, even as sentiment diverges across the broader healthcare sector.
Goldman Sachs analyst Asad Haider maintained a Buy rating on Eli Lilly & Co in a report released in late May, setting a price target of $1,283.00. At the time of the report, Eli Lilly shares had closed at $1,064.15. Haider, a 4-star analyst according to TipRanks, holds an average return of 17.3% and a 73.3% success rate across his coverage universe, which also includes NewAmsterdam Pharma Company, Bristol-Myers Squibb, and Johnson & Johnson.
The bullish sentiment was echoed by Truist Financial analyst Srikripa Devarakonda, who reiterated a Buy rating on Eli Lilly in a report issued on June 8. Shares closed at $1,163.73 on the Thursday preceding that report. Devarakonda, rated a 5-star analyst by TipRanks, boasts an average return of 17.2% and a 57.2% success rate.
Citi also maintained a Buy rating on Eli Lilly in a report issued on May 19, setting an even more ambitious price target of $1,500.00. Barclays followed suit, maintaining a Buy rating on May 26 with a $1,400.00 price target.
The analyst consensus on Eli Lilly currently stands at Strong Buy, with an average price target of approximately $1,267, representing an upside ranging from roughly 11% to nearly 19% depending on the reference share price at the time of each report.
Diverging Views Across Healthcare
While Eli Lilly enjoys broad analyst support, other healthcare companies have drawn more cautious assessments. Replimune Group (search) (NASDAQ: REPL) received a Hold rating from J.P. Morgan analyst Anupam Rama, with a price target of $8.00. The company's shares closed at $8.87 on the Tuesday preceding the report. The broader Street consensus for Replimune Group is a Hold, with an average price target of $4.20, representing a potential downside of approximately 52.8% from current levels. Leerink Partners also reiterated a Hold rating on the stock.
Novartis (NYSE: NVS) similarly received a Hold rating from TD Cowen analyst Steve Scala, with a price target of $180.00. Novartis shares closed at $154.09 ahead of the report. Scala, a 4-star analyst with an average return of 10.2% and a 62.8% success rate, covers Merck & Company, GlaxoSmithKline, and Eli Lilly & Co. The analyst consensus for Novartis is Moderate Buy, with a price target consensus of $171.84, implying a 13.1% upside.
Relay Therapeutics (NASDAQ: RLAY) bucked the cautious trend among smaller biotechs, with Goldman Sachs analyst Salveen Richter maintaining a Buy rating and a $22.00 price target. Shares closed at $15.70. JonesTrading also upgraded Relay Therapeutics to Buy with a $20.00 price target in a May 19 report. The consensus rating stands at Strong Buy with an average price target of $23.00, suggesting a 38.1% upside.
Insulet (search) (NASDAQ: PODD), a diabetes technology company, received a Buy rating from Truist Financial analyst Richard Newitter, who set a $219.00 price target. Shares closed at $149.95. The analyst consensus is Strong Buy with a price target of $229.35, representing a 52.9% upside. RBC Capital also maintained a Buy rating with a $280.00 target.
The contrasting analyst sentiments underscore the selective nature of healthcare investment in the current environment, with large-cap pharmaceutical leaders like Eli Lilly commanding strong conviction while smaller and mid-cap companies face more measured scrutiny.